(Q43740780)

English

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

phase II clinical trial

0 references

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Berg WJ

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Schwartz L

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Yu R

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mazumdar M

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

317-320

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

https://scigraph.springernature.com/pub.10.1023/a:1010609810517

0 references

Renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic chemotherapy for advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2000.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

1 reference

https://pubmed.ncbi.nlm.nih.gov/11561691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1010609810517

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43740780&oldid=2102961342"